Publication: The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact
Issued Date
2021-01-01
Resource Type
ISSN
17474094
17474086
17474086
Other identifier(s)
2-s2.0-85116057980
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Review of Hematology. Vol.14, No.12 (2021), 1059-1069
Suggested Citation
Chutima Kunacheewa, Elisabet E. Manasanch The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Expert Review of Hematology. Vol.14, No.12 (2021), 1059-1069. doi:10.1080/17474086.2021.1984225 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78600
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact
Author(s)
Other Contributor(s)
Abstract
Introduction: Multiple myeloma is preceded by the early stages: monoclonal gammopathy of unknown significance (M.G.U.S.) and smoldering myeloma (S.M.M.), which are less genomically complex and where patients are overall healthier with preserved quality of life. Areas covered: This review focuses on the current evidence in risk stratification and initial therapy for these patients with the goal to delay progression to and/or cure multiple myeloma. Expert opinion: Advances in the understanding of the factors that contribute to myeloma evolution coupled with new therapeutics that have high efficacy and limited toxicity have revolutionized our approach to early myeloma. Although our current recommendation continues to be to observe S.M.M. outside of clinical trials, the clinical benefit of lenalidomide sets the stage for combinations with immunotherapy, which, in our opinion, will likely lead to regulatory approvals and more widespread treatment of early myeloma.